Oprelvekin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : SC Prevention of severe thrombocytopenia after myelosuppressive chemotherapy; Reduce the need for platelet transfusions after myelosuppressive chemotherapy 50 mcg/kg/day. Give initial dose 6-24 hr after the last antineoplastic dose and continue for up to a max of 21 days. Discontinue at least 2 days before the next chemotherapy cycle.
Dosage Details
Subcutaneous
Prophylaxis of severe thrombocytopenia after myelosuppressive chemotherapy, Reduce the need for platelet transfusions after myelosuppressive chemotherapy
Adult: 50 mcg/kg daily. Give initial dose 6-24 hr after the last antineoplastic dose and continue treatment for up to a max of 21 days. Discontinue at least 2 days before the next chemotherapy cycle.
Renal Impairment
CrClDosage
<3025 mcg/kg daily.
Reconstitution
Reconstitute with sterile water for inj to a concentration of 5 mg/ml.
Contraindications
Do not use after myeloablative chemotherapy and bone marrow transplantation.
Special Precautions
History or signs of heart failure. Monitor fluid and electrolyte balance in patients on prolonged diuretic therapy. Pre-existing papilloedema or CNS tumours, pre-existing pericardial effusions or ascites. Hepatic, renal or respiratory impairment. History of stroke or thromboembolic disorders. Pregnancy and lactation.
Adverse Reactions
Tachycardia, oedema, palpitation, cardiomegaly, vasodilation, syncope, atrial arrhythmia; headache, dizziness, fever, insomnia, fatigue; rash; fluid retention; nausea/vomiting, diarrhoea, oral moniliasis; dilutional anaemia; weakness, arthralgia, periostitis; conjunctival inj/redness/swelling, papilloedema; dyspnoea, rhinitis, cough, pharyngitis; wt gain; pleural effusion.
Potentially Fatal: Anaphylactoid reactions.
Parenteral/SC: C
Overdosage
Symptoms: Increased CV events. Treatment: Symptomatic and supportive. Reinstitution of therapy should be based on individual patient factors (need for therapy and severity of toxicity).
Drug Interactions
Increased risk of adverse CV effects with diuretics (due to hypokalaemia).
Action
Description: Oprelvekin is a recombinant human interleukin-11 platelet factor that promotes growth and maturation of megakaryocytes, which increases the production of platelets.
Pharmacokinetics:
Absorption: Bioavailability: About 80% (SC). Peak serum concentrations after about 3 hr.
Excretion: Via urine (mainly as metabolites). Clearance reduced in renal impairment. Terminal half-life: 7 hr.
Storage
Store under refrigeration at 2-8°C (36-46°F). Do not freeze and protect from light. Reconstituted solution: Use within 3 hr of reconstitution and store in the original container at either 2-8°C (36-46°F) or ≤25°C (77°F). Do not freeze or shake.
Disclaimer: This information is independently developed by MIMS based on Oprelvekin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in